Evidence map›Paper›PMID 34743925›Full record

ArticleJournal of substance abuse treatment2022

Reducing tobacco use in substance use treatment: An intervention to promote tobacco-free grounds.

Caravella McCuistian, Kwinoja Kapiteni, Thao Le, Jessica Safier, Kevin Delucchi, Joseph Guydish

Open access · hybridAbstract read
In one paragraph

Article in Journal of substance abuse treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Caravella McCuistianPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, 490 Illinois St., Floor 7 San Francisco, CA 94158, United States of America. Electronic address: caravella.mccuistian@ucsf.edu.
Kwinoja KapiteniPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, 490 Illinois St., Floor 7 San Francisco, CA 94158, United States of America.
Thao LePhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, 490 Illinois St., Floor 7 San Francisco, CA 94158, United States of America. Electronic address: thao.le@ucsf.edu.
Jessica SafierSmoking Cessation Leadership Center, University of California San Francisco, 3333 California Street, Ste. 430, San Francisco, CA 94143, United States of America. Electronic address: jessica.safier@ucsf.edu.
Kevin DelucchiDepartment of Psychiatry, University of California San Francisco, 401 Parnassus Ave, San Francisco, CA 94143, United States of America. Electronic address: kevin.delucchi@ucsf.edu.
Joseph GuydishPhilip R. Lee Institute for Health Policy Studies, University of California San Francisco, 490 Illinois St., Floor 7 San Francisco, CA 94158, United States of America. Electronic address: joseph.guydish@ucsf.edu.
University of California, San Francisco · USLee University · US

Funding

Substance Use Disorders Treatment/Services Research Training ProgramT32DA007250 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Derek D Satre, Janice Y Tsoh · 1991 to 2026
$7.4M
NIDA NIH HHS T32 DA007250
6 · The paper itself

Abstract

backgroundPeople in substance use disorder (SUD) treatment experience disproportionate rates of tobacco use. California has prioritized smoking cessation among these individuals through the Tobacco-Free for Recovery Initiative, which includes an intervention aimed at supporting programs in implementing tobacco-free grounds. The current study examined changes in client smoking prevalence, tobacco use behaviors, and receipt of cessation services among the first seven programs participating in the initiative.

methodsResidential treatment program clients completed cross-sectional surveys at the start of the intervention (baseline: n = 249), at an interim timepoint post-baseline (interim: n = 275), and at the end of the intervention 15 months later (post-intervention: n = 219). All participants reported smoking status. Current smokers reported tobacco use behaviors, and both current smokers and those who quit in treatment reported receipt of cessation services. Univariate analyses explored differences across the three timepoints and multivariate logistic regression assessed change from baseline to interim and baseline to post-intervention.

resultsClient smoking prevalence decreased from 54.2% at pre- to 26.6% at post-intervention (Adjusted Odds Ratio [AOR] = 0.25, 95% CI = 0.13, 0.45). Current smokers and those who quit while in treatment reported an increase in NRT/pharmacotherapy (11.9% vs. 25.2%; AOR = 3.02, CI = 1.24, 7.35). When comparing baseline to the interim timepoint (a timepoint before the COVID-19 pandemic), data analyses also demonstrated a significant decrease in smoking prevalence (54.2% vs. 41.8%; AOR = 0.62, CI = 0.42, 0.92) and increase in NRT/pharmacotherapy (11.9% vs. 24.5%; AOR = 3.68, CI = 1.11, 12.19).

conclusionAn intervention to promote tobacco-free grounds implemented in residential SUD treatment programs was associated with a significant reduction in client smoking and an increase in NRT/pharmacotherapy. These associations were observed both before the COVID-19 pandemic and in the early stages of the pandemic, suggesting that they may be due to the intervention rather than to the pandemic.

Indexed as

COVID-19Substance-Related DisordersCross-Sectional StudiesHumansNicotianaPandemicsSARS-CoV-2Tobacco UsePolicySubstance use treatmentTobacco cessation

Identifiers

PMID34743925
PMCPMC8903046
OpenAlexW3210331684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.